ELAVL4, PARK10, and the celts

Movement Disorders

Volumn 22, Issue 4, 2007, Pages 585-587

  Haugarvoll, Kristoffer ^a,b,f   Toft, Mathias ^a,b   Ross, Owen A ^a   Stone, Jeremy T ^a   Heckman, Michael G ^a   White, Linda R ^b   Lynch, Timothy ^c   Gibson, John Mark ^d   Wszolek, Zbigniew K ^a   Uitti, Ryan J ^a   Aasly, Jan O ^b,e   Farrer, Matthew J ^a  

^a MAYO CLINIC   (United States)

^b NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^c MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

^d ROYAL VICTORIA HOSPITAL   (United Kingdom)

^e TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^f MAYO GRADUATE SCHOOL   (United States)

Author keywords

ELAVL4; Genetics; PARK10; Parkinson's disease

Indexed keywords

ELAV LIKE PROTEIN 4; NUCLEIC ACID BINDING PROTEIN; PARK10 PROTEIN; PEPTIDES AND PROTEINS; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CORRELATIONAL STUDY; DISEASE PREDISPOSITION; FEMALE; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; ONSET AGE; PARKINSON DISEASE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ALLELES; FEMALE; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; HU PARANEOPLASTIC ENCEPHALOMYELITIS ANTIGENS; HUMANS; LINKAGE (GENETICS); MALE; MIDDLE AGED; NORWAY; PARKINSON DISEASE; POINT MUTATION; PROTEIN-SERINE-THREONINE KINASES; UBIQUITIN-PROTEIN LIGASES; UNITED STATES;

EID: 34247249296     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.21336     Document Type: Article

References (14)

1. Farrer MJ. Genetics of Parkinson disease: paradigm shifts and future prospects. Nat Rev Genet 2006;7:306-318.
2. Hicks AA, Petursson H, Jonsson T, et al. A susceptibility gene for late-onset idiopathic Parkinson's disease. Ann Neurol 2002;52:549-555.
3. Li YJ, Scott WK, Hedges DJ, et al. Age at onset in two common neurodegenerative diseases is genetically controlled. Am J Hum Genet 2002;70:985-993.
4. Noureddine MA, Qin XJ, Oliveira SA, et al. Association between the neuron-specific RNA-binding protein ELAVL4 and Parkinson disease. Hum Genet 2005;117:27-33.
5. Antic D, Keene JD. Embryonic lethal abnormal visual RNA-binding proteins involved in growth, differentiation, and posttranscriptional gene expression. Am J Hum Genet 1997;61:273-278.
6. Goodacre S, Helgason A, Nicholson J, et al. Genetic evidence for a family-based Scandinavian settlement of Shetland and Orkney during the Viking periods. Heredity 2005;95:129-135.
7. Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. Arch Neurol 1999;56:33-39.
8. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005;21:263-265.
9. Gabriel SB, Schaffner SF, Nguyen H, et al. The structure of haplotype blocks in the human genome. Science 2002;296:2225-2229.
10. Oliveira SA, Li YJ, Noureddine MA, et al. Identification of risk and age-at-onset genes on chromosome lp in Parkinson disease. Am J Hum Genet 2005;77:252-264.
11. Greenway MJ, Andersen PM, Russ C, et al. ANG mutations segregate with familial and 'sporadic' amyotrophic lateral sclerosis. Nat Genet 2006;38:411-413.
12. Haugarvoll K, Wszolek ZK. PARK8 LRRK2 Parkinsonism. Curr Neurol Neurosci Rep 2006;6:287-294.
13. Di Fonzo A, Wu-Chou YH, Lu CS, et al. A common missense variant in the LRRK2 gene, Gly2385Arg, associated with Parkinson's disease risk in Taiwan. Neurogenetics 2006;7:133-138.
14. Farrer MJ, Haugarvoll K, Ross OA, et al. Genomewide association, Parkinson disease, and PARK10. Am J Hum Genet 2006;78:1084-1088; author reply 1092-1094.